Equity

WEEKLY COVID VACCINE RESEARCH UPDATE Friday, June 11, 2021 High-income country confirmed dose total: 6 billion Upper-middle-income country total: 2.2 billion Lower-middle-income country total: 1.4 billion Low-income country total: 271 million COVAX total: 2.4 billion Total worldwide confirmed purchases of Covid-19 vaccines: 12.2 billion doses INSIGHTS How can India address a potential third wave of SARS-CoV-2 infections? Author: Nikki Prattipati Starting mid-March 2021, India has become the epicenter of COVID-19 as a second wave of infections devastated the country. India reported 50 percent of global cases and 30 percent of global COVID-19 deaths, and an alarming rate of over 400,000 daily new cases at the height of the wave in early May 2021. While official projections estimate 29 million total infections and 360,000 deaths, low testing rates and the lack of available data lead some…

WEEKLY COVID VACCINE RESEARCH UPDATE Friday, June 4, 2021 [caption id="attachment_1629" align="alignnone" width="300"] Coronavirus and DNA, virus mutation. New variant and strain of SARS CoV 2. Microscopic view. 3D rendering[/caption] High-income country confirmed dose total: 6 billion Upper-middle-income country total: 2.2 billion Lower-middle-income country total: 1.1 billion Low-income country total: 270 million COVAX total: 2.4 billion Total worldwide confirmed purchases of Covid-19 vaccines: 11.9 billion doses INSIGHTS How do COVID-19 variants impact vaccinations and the ability to end the acute phase of the pandemic? Author: Blen Biru Multiple COVID-19 genetic variants have been detected since the initial SARS-CoV-2 strain was found in China, the most significant of which are classified by the WHO as variants of concern or variants of interest, depending on their attributes and risk level. The variants of concern are…

WEEKLY COVID VACCINE RESEARCH UPDATE Saturday, May 15, 2021 INSIGHTS What the manufacturing landscape can tell us now Author: Andrea Taylor Manufacturing projections for Covid-19 vaccines seem to shift on a near-weekly basis. We are not even halfway into 2021 and already we have seen adjustments, both up and down, across all vaccine makers. 2021 projections differ by vaccine platform Overall, we see 2021 projections increasing for mRNA vaccines Pfizer-BioNTech and Moderna, while decreasing for viral vector vaccines Oxford-AstraZeneca and Janssen (J&J). AstraZeneca, in particular, has faced significant manufacturing issues throughout its global production network. In addition to the well-covered constraints slowing down manufacturing in Europe and the Serum Institute of India, partners in Mexico, Brazil, and elsewhere have struggled to get production started or sustained. Janssen’s vaccine has also experienced setbacks, including the temporary…